We are very excited to present the final schedule for the
International Conference On Opioids
(
ICOO2015
) titled:
Opioids: An Evolving Paradigm - Challenges and Solutions
If you are involved with prescribing or managing patients on opioids, you should attend this conference. Opioids and their applications are rapidly evolving due to pressure from many sources. Attend
ICOO2015, learn from leaders and be on the leading edge of this change!
We invite your review of the entire
schedule below! Join us!
|
Sunday, June 7, 2015
Conference Hours 8:30 am - 5:30 pm, Registration open 7:00 am - 5:00 pm |
8:30 am - 9:00 am
Conference Opening and Welcome
Paul A. Sloan, MD & Mellar Davis, MD
|
9:00 am - 10:30 pm
OPIOID REMS Training Part A
Intensive training on ER/LA Opioids
Great primer and/or refresher program
Paul A. Sloan, MD & Mellar Davis, MD
|
10:30 am - 11:00 am
Break with Exhibitors and Poster Presenters
|
11:00 am - 12:30 pm
OPIOID REMS Training Part B
Paul A. Sloan, MD & Mellar Davis, MD
|
12:30 pm - 1:30 pm
Lunch Break with Exhibitors, Poster Presenters or Satellite Symposia
Lunch provided by ICOO2015 organizers - not industry sponsored |
12:30 pm - 1:30 pm
Satellite Symposia
THE OPIOID EPIDEMIC CONTINUUM:
ASSESSING AND PREVENTING THE RISK OF OVERDOSE
IN THE MEDICAL USE OF OPIOIDS.
The US Center for Disease Control reports that drug overdose death rates have more
than doubled between 1999 and 2013. In 2013, 71.3% of deaths from pharmaceutical overdose involved opioid analgesics. Methods to mitigate the risk of opioid overdose
across multiple healthcare settings are needed.
Opioid overdose can occur both in patients prescribed opioids for pain and persons
using prescription opioids diverted from medical use; overdoses can occur due to misunderstanding, accident, or intentional overuse and are not limited to individuals
addicted to opioids. In an effort to control opioid overdose, which results globally
in an estimated 69,000 deaths per year, the World Health Organization recommends increasing access to naloxone.
This session will use case studies to review the identification of the at-risk patient and strategies to reduce prescription opioid overdose risk, focusing on the role of naloxone.
It will review requisite counseling for potential users of naloxone and arguments
for selective versus universal co-prescribing of naloxone with opioids. Diverse
state-mandated regulations governing availability of naloxone and liability protection
for prescribers and administrators will be explored. Attitudes, approaches,
and barriers to co-prescribing naloxone will be addressed so that this approach
can be better understood and appropriately utilized.
Bob Twillman
1, Seddon Savage
2
1 American Academy of Pain Management,
2
Dartmouth Medical School & Silver Hill Hospital
Non-CME Symposia sponsored by Indivior PLC
|
1:30 pm - 2:15 pm
Intrathecal and epidural administration of opioids in therapy-resistant
cancer pain syndromes: indications and practical considerations?
In this presentation the experience from a university-based pain center will be provided (covering over 100 patients) with the intrathecal administration of opioids in cancer pain syndromes which were resistant to (high doses of) systemic opioids.
Guy Hans, MD, PhD, Paul A. Sloan, MD
|
2:15 pm - 3:00 pm
Reducing Opioid Misuse Among Chronic Pain Patients In Primary Care
This presentation will include the results of a prospective controlled trial
designed to examine the benefits of careful monitoring
of chronic pain patients within primary care.
Robert Jamison, PhD |
3:00 pm - 3:30 pm
Pharmacogenomics of Opioids: Clinical Translation is Premature
For opioids requiring CYP2D6 to form active metabolites, poor metabolizers
should have no pain reduction but this has not been shown clinically.
Ultrarapid metabolizers have toxicity. The mu receptor gene 118A>G
causes higher dosage requirements. Clinical translation of opioid genetics
is premature as many pain and addiction phenotype factors contribute.
Andrew Somogyi, MD |
3:30 pm - 4:00 pm
Break with Exhibitors and Poster Presenters |
4:00 pm - 4:45 pm
Morphine-triggered relapse to cocaine-seeking behavior in laboratory rats
is attenuated by a highly-selective dopamine D3 receptor antagonist
Re-exposure to addictive drugs triggers relapse. Cross-triggering between drug classes is common (e.g., opioids triggering cocaine or amphetamine craving). Dopamine D3 receptor antagonists show extraordinary promise as anti-addiction medications in animal models. The D3 antagonist SB277011A significantly attenuates morphine-triggered relapse to cocaine-seeking behavior in the conditioned place preference animal model.
Eliot Gardner, PhD, Onarae Rice, PhD,
Christian Heidbreder, PhD, Charles Schonhar, BA |
4:45 pm - 5:30 pm
Transforming Opioid Prescribing Practice at a Comprehensive Cancer Center
We sought to examine opioid prescribing practices by clinician survey at a comprehensive cancer center (CCC). A task force was convened to examine the issue and a Medication Management Agreement (MMA) and patient education document were created. We hoped to transform prescribing practices within a population of oncology patients.
Lida Nabati, MD, Douglas Brandoff MD |
|
Monday, June 8, 2015
Conference Hours 8:00 am - 5:15 pm, Registration open 7:00 am - 5:00 pm |
8:00 am - 8:45 am
Keynote: Methadone maintenance:
An effective treatment for opioid addiction & for chronic pain
Mary Jeanne Kreek, MD |
8:45 am - 9:15 am
Methadone: Update on Safety and Dosing Guidelines
The American Pain Society and other groups recently published safety guidelines
on methadone dosing and suggested monitoring parameters. This presentation will provide an overview of these guidelines and will include case-based illustrative examples. Application in special populations such as end of life care will also be addressed.
Mary Lynn McPherson, PharmD, BCPS,CPE |
9:15 am - 9:45 am
New Drugs and Drug News in Pain Management
Over 100 new drugs and dosage formulations are approved by the FDA every year, and many of them are used to relieve pain or analgesic-induced adverse effects. This presentation will provide cutting-edge, practical information on these products and their appropriate use.
Mary Lynn McPherson, PharmD, BCPS,CPE |
9:45 am - 10:15 am
Oxycodone/Naloxone PR Combination Analgesic:
Where does it Belong in the Opioid Therapy?
This presentation will review the pharmacology and evidence for Targiniq ER in non-cancer chronic pain, cancer pain, neuropathic pain and postoperative pain.
A critique will be made of studies and then the potential place of this analgesic
in opioid therapy will be outlined based on the data.
Mellar Davis, MD |
10:15 am - 10:45 am
Break with Exhibitors and Poster Presenters
|
10:45 am - 11:30 am
Dodging Elusive and Miscalculated Opioid Risks:
A Primer on Pharmacogenetics and Unsuspected Drug Interactions
(with prescribed and illicit synthetics)
Fatal drug interactions between opioids and sedative-hypnotics have been well publicized and studied. Less publicized are serious drug interactions between pain medications and illicit synthetic designer drugs. Pharmacologic interactions between prescription opioids and synthetics have not been studied extensively. Unsuspected pharmacogenetic and p-gylocoprotein interactions also is largely underappreciated by clinicians.
Jeffrey Fudin, BS,PharmD,DAAPM,FCCP |
11:30 am - 12:30 pm
Keynote: Opioid Epidemic in Massachusetts
Governor Charlie Baker will speak about the opioid abuse epidemic in Massachusetts
and the goals of the Opioid Addiction Working Group.
Massachusetts Governor Charlie Baker |
12:30 pm - 1:30 pm
Lunch Break with Exhibitors, Poster Presenters or Satellite Symposia
Lunch provided by ICOO2015 organizers - not industry sponsored
|
12:30 pm - 1:30 pm
Satellite Symposia
Development and Validation of a Risk Index
for Prescription Opioid Overdose
and Serious Opioid-related Respiratory Depression
Eric Edwards, MD, PhD
Chief Medical Officer and VP Research & Development
Non-CME Symposia sponsored by kal?o |
1:30 pm - 2:00 pm
Basic science of variability in opioid responses and analgesic tolerance:
Bridging basic science to clinical relevance
Gavril Pasternak, MD |
2:00 pm - 2:30 pm
Chronic Pain Patients Who Fail Standard Opioid Dosages
There is a subgroup of severe chronic pain patients who fail to achieve pain relief
with standard opioid dosages of about 80 to 100 mg of morphine equivalence a day.
Our studies show that these patients have significant hormonal, genetic,
or metabolic abnormalities that help explain their treatment failure.
Forest Tennant, MD, DrPH |
2:30 pm - 3:15 pm
Legal issues from a physician's viewpoint
Carol Warfield, MD, Michael Barnes, Esq. |
3:15 pm - 3:45 pm
Break with Exhibitors and Poster Presenters
|
3:45 pm - 4:30 pm
Perioperative Pain Management of Opioid Dependent Patients
Opioid dependent patients pose a considerable challenge to the perioperative physician. Pain management is a major concern in such patients. The speakers will address the magnitude of the problem, clinical and pathophysiological aspects, and management options while dealing with patients with opioid dependence.
Nalini Vadivelu, MBBS, MD, DNB, Lucy Chen, MD, Karina Gritsenko, MD |
4:30 pm - 5:15 pm
Pain Management in Patients with Opioid Use Disorders
Pain management often presents a challenge in patients with alcohol or drug use disorders, especially opioid use disorders. Treatment of opioid dependence with naltrexone, buprenorphine or methadone can further complicate matters. This presentation will discuss therapeutic approaches, with an emphasis on opioid therapy, to pain management in patients with opioid dependence.
Aleksandra Zgierska, MD, PhD |
|
6:00 pm - 8:00 pm
Special IAPCD Dinner Presentation
Optimizing Treatment for Opioid-addicted Adolescents and Young Adults:
The State of the Evidence
This presentation will characterize treatment-seeking youth addicted to prescription (and other) opioids, introduce participants to two model treatment programs, and review the state of the scientific literature on the treatment of prescription (and other) opioid dependence
among adolescents and young adults.
Sarah K. Moore, PhD, Senior Researcher, Capital Health Medical Center
Karen Carlini, CASAC, Associate Director, Dynamic Youth Community, Inc.
Sharon Levy, MD, Director, Adolescent Substance Abuse Pgm, Children's Hospital
Lisa A. Marsch, PhD, Director, Center for Tech & Behavioral Health, Dartmouth College
(Additional Fee to Participate, Click here for Invitation) |
|
Tuesday, June 9, 2015
Conference Hours 8:00 am - 1:15 pm, Registration open 7:00 am - 12:00 pm |
8:00 am - 8:45 am
Sigma-1 Receptors: Important Modulators Of Opioid Responses
and the Development of Sigma-1 Receptor Antagonists as Co-analgesics.
Sigma-1 receptors are endoplasmic reticulum mobile receptors which are tonically active anti-opioid modulators. SIRA, A Sigma-1-receptor blocker with development. These unique receptors were initially thought to be opioid receptors because they were bound by dextrorotatory benzomorphan derivatives [ (+) pentazocine]. They are now known to be important modulators of opioid responses.
Mellar Davis, MD, Gavril Pasternak, MD |
8:45 am - 9:30 am
Meeting Opioid Guideline Prescribing Requirements
This workshop will provide a hands on look at the tools, techniques and work flows for a physician practice to meet opioid prescribing guidelines.
William Brose, MD |
9:30 am - 10:00 am
Improving Utilization and Outcomes of Urine Drug Testing
This session will provide an overview of appropriate use of urine drug testing (UDT) to identify and treatment substance use. Proper utilization can improve quality, reduce costs, and expand consumer access to treatment.
Michael Barnes, Esq., Andrea Barthwell, MD, FASAM |
10:00 am - 10:45 am
A primer and latest applications of urine drug testing
Gary M. Reisfield, MD |
10:15 am - 10:45 am
Break with Exhibitors and Poster Presenters
|
11:00 am - 11:30 am
Selected Poster Presentations to audience
|
| 11:30 am - 1:00 pm
Opioid Analgesia and Marijuana - Questions of Balance
A balanced discussion of issues surrounding cannabis use by the chronic pain patient using opioid pharmacotherapy - including considerations of medical-scientific facts and fiction about cannabis; legal-regulatory issues relevant to cannabis and its various use scenarios; ethical questions confronting clinicians caring for cannabis users; research on cannabis including its possible use to potentiate opioid analgesia.
Larry Driver, MD, Michael Schatman PhD |
1:00 pm - 1:15 pm
Conference Closing Remarks
Paul A. Sloan, MD, Mellar Davis, MD
|
| *Conference schedule and topics subject to change without notice |
|
We are very excited that
Massachusetts Governor Charlie Baker
, will speak at the
International Conference On Opioids
(
ICOO2015
) and share details about the
Opioid Addiction Working Group
tasked to formulate a state-wide strategy to combat opioid abuse and deaths.
Governor Baker has a unique background as past CEO of Harvard Pilgrim Health Care, and now as Governor, he can integrate the social as well as financial costs of opioid abuse.
Join us!
Don't miss the new IAPCD dinner session,
"
Optimizing Treatment for Opioid-addicted Adolescents and Young Adults: The State of the Evidence"
Join us June 7-9 at the
2015 International Conference on Opioids
for the best peer-led education and networking.
Over 22 sessions, a keynote from Mary Jeanne Kreek, MD, Governor Baker and 28 other leading educators in the field of opioid education.
Register now and book your hotel quickly for best rates and options.
Click here
to join our new
International Conference on Opioids Linkedin? group and receive conference program highlights as well as registration offers.
The
International Conference on Opioids (ICOO 2015)
is a must-attend event for anyone in healthcare who has a commitment to the proper and appropriate use of these powerful analgesics. This is the conference to address leading issues and breakthrough research on opioids, designed in an intimate setting complete with education and networking.
I
COO 2015 will allow you to gain insights into the future of opioid therapies. Read the
(FULL SCHEDULE)
Special rates available for residents, students, RNs, PAs and NPs.
Subscribers to the Journal of Opioid Management receive an additional $50 discount.
Explore the full conference agenda at
|
 |
|
Bring two colleagues
with you!
Save an additional
$50 each
|
|
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Dannemiller and Weston Medical Publishing, LLC. Dannemiller is accredited by the ACCME to provide continuing medical education for physicians. Dannemiller designates this live activity for a maximum of 18
AMA PRA Category 1 Credit(s)?. Physicians should claim only the credit commensurate with the extent of their participation in the activity. RN Credit: Dannemiller is a provider approved by the California Board of Registered Nursing, Provider Number 4229. This activity has been approved for up to 18 contact hours. CBRN credit is not accepted by the Michigan and Utah State licensing boards.
Jointly Provided by Dannemiller and Weston Medical Publishing, LLC.
 Dannemiller, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is an application based activity. Dannemiller has assigned 18.0 contact hours (1.8 CEUs) of continuing pharmacy education credit to this activity. ACPE program number 0522-9999-15-015-L01-P.
Linkedin is a registered trademark of Linkedin Corporation.
|
|
|
|
Where
Joseph B. Martin Conference Center
at Harvard Medical School
77 Avenue Louis Pasteur
Boston, MA 02115
|
Dynamic 2+ day program featuring renowned specialists presenting new data, essential information and best practices every medical professional needs to know when prescribing opioid analgesics for their patients. View More Info
Registration Fee:
Registration Rate:
$645 per person. Join our Linkedin group for special offers and conference highlights.
Special rates available for residents, students, RNs, PAs and NPs.
Journal of Opioid Management subscribers receive a $50 discount off the registration fees above.
Please enter your subscriber ID in the special instructions
box at the checkout to receive the discount.
Register Online:
Register by Phone:
Call our reservation desk at 781-899-2702 x 108
Register by Fax:
Fax: 781-899-4900
24 hrs./day, via secure fax
Register by Mail:
I
nternational Conference on Opioids
470 Boston Post Road
Suite 301
Weston, MA 02493 USA
|
|
|
|
